Considering trial setbacks and cash concerns, Satsuma Pharmaceuticals faced an uphill climb to even file for approval of its migraine spray treatment at the FDA. Now, the agency has thrown another ...
New device, new trial, same flop. That is the story at Satsuma Pharmaceuticals, which suffered a second stock-crushing phase 3 belly-flop after tweaks to its migraine nasal drug delivery device failed ...
Satsuma Pharmaceuticals is hunkering down while searching for a savior. After opting against trying to commercialize a migraine candidate itself, the biotech has outlined plans to lay off 36% of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results